NCT05122975招募中2 期
Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- The effect of S48168 (ARM210) treatment on the amount and complexity of exercise-• Change in ectopy score from baseline to Day 28 versus placebo (pre-dose Period 1 baseline to Day 28 Period 1 versus Day 28 Period 2
研究概览
简要总结
The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease is associated with fatal changes in heart rhythms leading to sudden death with exercise or excessive excitement. It is due to mutations in the Ryanodine Receptor calcium release channel, which cause leaky channels leading to the disease. S48168 (ARM210) repairs these leaky channels and can be a disease-modifying therapy restoring normal function to the channels. This result would allow patients with CPVT to live normal, active lives. Funding Source- FDA OOPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
S48168 and exact matching placebo
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all the following conditions to be eligible for enrollment into the study:
- •Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
- •Participants who are willing and able to comply with scheduled visits, study drug administration plan, study restrictions, and study procedures.
- •Participants have a confirmed genetic diagnosis of CPVT1 and supporting clinical phenotype, including residual ventricular ectopy (a complexity score ≥ 2; requiring at minimum the presence of PVCs in bigeminy on exercise stress test) on a stable (at least 1 month) standard-of-care, CPVT1-directed treatment regimen as decided by their CPVT treating physician.
- •Have a body mass index (BMI) ≤ 36 kg/m2 (inclusive) at screening.
- •Male participants agree to not donate sperm from the first day of dosing of study drug until 5 half-lives plus 90 days (approximately 94 days) after the last dose of study drug.
- •Female participants:
- •eligible to participate if she is not pregnant or breastfeeding, and uses one of the following highly effective birth control methods (from the first dose until 5 half-lives plus 90 days (approximately 94 days):
- •Prescribed hormonal oral contraceptives, vaginal ring, or transdermal patch.
- •Intrauterine device (IUD).
- •Intrauterine hormone-releasing system (IUS).
- •Depot/implantable hormone (e.g., Depo-Provera®, Implanon).
- •Bilateral tubal occlusion/ligation.
- •Sexual abstinence.
- •Refraining from heterosexual intercourse during the entire period of risk associated with the study requirements.
- •If the participant decides to become sexually active during the study, then one of the highly effective birth control methods must be used.
- •Is a woman of non-childbearing potential; defined by at least 1 of the following criteria:
- •Postmenopausal defined as 12 months of spontaneous amenorrhea without a medical cause and follicle stimulating hormone (FSH) serum level > 40 mIU/mL without the use of hormonal supplementation. Appropriated documentation of FSH levels is required.
- •Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation of surgical procedure.
- •Has a congenital condition resulting in no uterus.
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
- •Daily use of medicines and dietary supplements need to be approved by the PI and Sponsor, or a drug/supplement-dependent wash-out prior to inclusion.
排除标准
- •The presence of any of the following conditions will exclude a participant from study enrollment:
- •History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose of study drug.
- •History or presence of hypersensitivity or idiosyncratic reaction to the study drug, related compounds, or inactive ingredients.
- •ALT or AST levels three times above the upper limits of normal (ULN) at screening (isolated elevations of total bilirubin < 2 X ULN with direct bilirubin below the ULN will be included). A recheck for confirmation is allowed.
- •History of documented, EEG-confirmed epileptic seizures.
- •History of cancer (malignancy). Exceptions: (1) Subjects with adequately treated non-melanomatous carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) Subjects with other malignancies who have been successfully treated > 10 years prior to the screening where in the judgment of the investigator has revealed no evidence of recurrence from the time of treatment through the time of the screening except those identified at the beginning of the exclusion criterion; or (3) Subjects who in the opinion of the investigator are highly unlikely to sustain a recurrence for the duration of the trial.
- •Currently has uncontrolled diabetes defined as HbA1c > 7% at screening visit or diabetic neuropathy.
- •Estimated creatinine clearance < 40mL/minute at screening visit.
- •Clinically significant abnormality on their screening and/or prior to first dosing resting ECG, other than hypertensive related, or heart failure (ejection fraction < 30%) or other clinically significant structural heart disease.
- •History of myocardial infarction in the last five years, or evidence of congestive heart failure.
- •Ongoing medical condition that is deemed by the PI to interfere with the conduct or assessments of the study or safety of the subject.
- •Unable to refrain from or anticipates the use of:
- •Any non-approved medicines (prescribed standard-of-care for CPVT is approved) and/or dietary supplements beginning 14 days prior to the first dose of study drug and throughout the study. Thyroid hormone replacement medication may be permitted if subject has been on same stable dose for the last 3 months prior to the first dose of study drug.
- •Any drugs known to be significant inducers or inhibitors of CYP2C8 enzymes for 28 days prior to the first dose of study drug and throughout the study. Is currently taking any drug which raises gastric pH, including proton pump inhibitors or H2 antagonists. Antacids may be used if taken at night.
- •Participation in clinical trials for other therapeutic investigational drugs simultaneously or within the 4 weeks prior to the first dose of study drug.
- •Plasma donation within 7 days prior to the first dose of study drug.
- •Donation of blood or significant blood loss within 56 days prior to the first dose of study drug.
- •Is mentally or legally incapacitated at the time of screening visit.
- •Is unable to take orally administered tablets.
- •Is an immediate family member of the Sponsor or employee of the clinical site or may consent under duress.
研究组 & 干预措施
S48168 (ARM210) once daily for 28 days
Experimental
Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
干预措施: S48168 (ARM210) (Drug)
Matching Placebo once daily for 28 days
Placebo Comparator
Oral dose of placebo once daily on top of standard of care regimen for 28 days.
干预措施: Matching Placebo (Drug)
结局指标
主要结局
The effect of S48168 (ARM210) treatment on the amount and complexity of exercise-• Change in ectopy score from baseline to Day 28 versus placebo (pre-dose Period 1 baseline to Day 28 Period 1 versus Day 28 Period 2
时间窗: 28 days
Analysis of ECG recordings during exercise testing examining for abnormal beats occurring with exercise, such as premature ventricular contractions (PVCs). The scale is as follows: Ectopy Scoring Scale (0-4) No ectopy 0 Isolated PVCs 1 Bigeminy 2 Couplets 3 Non-sustained VT 4 van der Werf, C., et al. (2011). "Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia." J Am Coll Cardiol 57(22): 2244-2254.
次要结局
- Incidence of Treatment-Emergent Adverse Events(28 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.SciaticaNCT01405833Biogen56
撤回
1 期
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal AdenocarcinomaStage II Rectal CancerStage III Rectal CancerNCT01302613University of Texas Southwestern Medical Center
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy SubjectsChronic HBV InfectionNCT05468060Zhejiang Palo Alto Pharmaceuticals, Inc.80
终止
2 期
Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn InjuryChronic Pain Following Thermal Burn InjuryNCT03313076University of North Carolina, Chapel Hill24
招募中
1 期
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of LymphomaRecurrent or Refractory B-cell Non Hodgkin's LymphomaNCT06503211The First Affiliated Hospital with Nanjing Medical University10